Informing Pharmaceutical Innovation Policy: The Health Value of R&D Cost Transparency

Good pharmaceutical innovation policy requires good data about R&D costs. By looking at the economics of the pharmaceutical R&D process, with the use of accurate data about costs, risks, and returns, policymakers can more accurately respond to competing claims for access and incentives to innovate and find ways of promoting affordable, accessible, and innovative drugs while discouraging redundant investments in high cost, low value added drugs. If our pharmaceutical innovation policy goal is truly to make positive contributions to public health, this kind of data should be readily available in usable forms for all drugs and should be used to inform public spending and the design of regulatory incentives.

Authors

Institutions

Publication Details

Journal
The Journal of Law Medicine & Ethics
Published
2026-11-19
DOI
https://doi.org/10.1017/jme.2026.10297
Primary Topic
Pharmaceutical Economics and Policy
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Informing Pharmaceutical Innovation Policy: The Health Value of R&D Cost Transparency

Liza Vertinsky
The Journal of Law Medicine & Ethics
Pharmaceutical Economics and Policy
article

Informing Pharmaceutical Innovation Policy: The Health Value of R&D Cost Transparency

Liza Vertinsky
article en

Abstract

Good pharmaceutical innovation policy requires good data about R&D costs. By looking at the economics of the pharmaceutical R&D process, with the use of accurate data about costs, risks, and returns, policymakers can more accurately respond to competing claims for access and incentives to innovate and find ways of promoting affordable, accessible, and innovative drugs while discouraging redundant investments in high cost, low value added drugs. If our pharmaceutical innovation policy goal is truly to make positive contributions to public health, this kind of data should be readily available in usable forms for all drugs and should be used to inform public spending and the design of regulatory incentives.

The Journal of Law Medicine & Ethics
University of Maryland, Baltimore (US)
Pharmaceutical Economics and Policy
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon